Today, new-generation cancer drugs have significantly improved both effectiveness and safety, especially targeted therapies.

Vial, a clinical-stage biotech company, today announced growing enthusiasm among metabolic disease KOLs for Vial's INHBE siRNA, a first-in-class, liver-targeted (GalNAc-conjugated) siRNA therapy that ...

Paralyzed Veterans of America Chief Executive Officer Carl Blake released a statement following Department of Veterans Affairs Secretary Doug Collins' announcement of a significant reorganization to ...

Policy swings have made it a slippery year for pharma ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Halozyme HALO3.44%increase; green up pointing triangle was granted a preliminary injunction that would prevent Merck MRK 0.40%increase; green up pointing triangle & Co. from distributing a formulation ...

Merck's cholesterol pill enlicitide ​decanoate and its cancer therapy sacituzumab tirumotecan, or sac-TMT, have been tapped ...

SAN DIEGO, Dec. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction ordering Merck ...

On the heels of striking a deal with the Trump administration to reduce the prices of several of its most popular drugs for U.S. patients, Eli Lilly has unveiled additional savings for cash-paying ...